News
Dr. Stacey Stein on Key Considerations When Selecting an Immunotherapy Approach in HCC
Stacey Stein, MD, Associate Professor of Medicine (Medical Oncology) Assistant Medical Director, Clinical Trials Office, Yale Cancer Center and Smilow Cancer Hospital, discusses key considerations when selecting a first-line treatment approach for higher-risk patients with hepatocellular carcinoma (HCC), as well as whether the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) is a viable approach in this population.
When navigating treatment options in HCC, physicians must evaluate whether the patient is a viable candidate for immunotherapy using standardized inclusion and exclusion criteria, Stein says. Although these guidelines have been well-established in the field, some situations may require clinical judgment, she notes. It is also critical to consider the management of any immunotherapy-related toxicities if selecting this option, Stein adds.
Source: OncLive